American Financial Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

American Financial Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.9M	Sell	24,664 -3,308	-12%	-$447K	0.47%	33
2026 Q1	$3.57M	Sell	27,972 -772	-3%	-$96.4K	0.48%	31
2025 Q4	$3.5M	Sell	28,744 -6,960	-19%	-$798K	0.45%	31
2025 Q3	$3.58M	Sell	35,704 -10,357	-22%	-$933K	0.46%	31
2025 Q2	$3.82M	Sell	46,061 -1,366	-3%	-$109K	0.53%	30
2025 Q1	$3.85M	Sell	47,427 -826	-2%	-$73.8K	0.56%	30
2024 Q4	$4.35M	Sell	48,253 -4,352	-8%	-$422K	0.61%	30
2024 Q3	$5.2M	Sell	52,605 -3,193	-6%	-$314K	0.71%	29
2024 Q2	$5.17M	Sell	55,798 -8,089	-13%	-$725K	0.74%	28
2024 Q1	$6.06M	Sell	63,887 -5,298	-8%	-$492K	0.85%	28
2023 Q4	$6.18M	Sell	69,185 -6,930	-9%	-$515K	0.91%	27
2023 Q3	$5.56M	Sell	76,115 -30,618	-29%	-$2.45M	0.88%	27
2023 Q2	$8.88M	Sell	106,733 -145,262	-58%	-$12.1M	1.39%	22
2023 Q1	$19.2M	Sell	251,995 -11,208	-4%	-$930K	3.13%	12
2022 Q4	$21.8M	Sell	263,203 -7,483	-3%	-$606K	3.7%	12
2022 Q3	$21.5M	Sell	270,686 -9,431	-3%	-$795K	3.71%	11
2022 Q2	$20.8M	Sell	280,117 -8,366	-3%	-$628K	5.52%	8
2022 Q1	$25.9M	Buy	288,483 +46,255	+19%	+$4.27M	3.6%	13
2021 Q4	$27.1M	Buy	242,228 +5,298	+2%	+$639K	3.45%	12
2021 Q3	$29.8M	Buy	236,930 +25,386	+12%	+$3.27M	3.98%	8
2021 Q2	$28.6M	Buy	211,544 +9,790	+5%	+$1.29M	3.94%	8
2021 Q1	$27.4M	Buy	201,754 +23,407	+13%	+$3.5M	4.07%	8
2020 Q4	$25.1M	Buy	178,347 +2,682	+2%	+$344K	3.58%	6
2020 Q3	$19.6M	Sell	175,665 -8,162	-4%	-$915K	3.18%	11
2020 Q2	$20.6M	Sell	183,827 -7,465	-4%	-$735K	3.3%	10
2020 Q1	$18.8M	Sell	191,292 -7,041	-4%	-$623K	3.37%	10
2019 Q4	$15.2M	Buy	198,333 +41,044	+26%	+$3.55M	2.66%	16
2019 Q3	$12M	Buy	157,289 +1,688	+1%	+$140K	2.27%	18
2019 Q2	$13.6M	Buy	155,601 +1,279	+0.8%	+$109K	2.66%	16
2019 Q1	$14M	Sell	154,322 -25,184	-14%	-$2.14M	2.85%	15
2018 Q4	$12.9M	Buy	+179,506	New	+$14.5M	2.82%	16

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

American Financial Advisors's XBI Position: Q2 2026 in Review

American Financial Advisors reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 12% in Q2 2026, selling an estimated $447K and leaving 24,664 shares worth $3.9M. The position accounts for 0.47% of the portfolio, ranked #33.

American Financial Advisors first reported a position in XBI in Q4 2018 and has held it in 31 quarters since. The position peaked at $29.8M in Q3 2021. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

American Financial Advisors held 24,664 shares of State Street SPDR S&P Biotech ETF worth $3.9M as of Q2 2026.
American Financial Advisors sold 3,308 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $447K.
State Street SPDR S&P Biotech ETF made up 0.47% of American Financial Advisors's portfolio in Q2 2026, its #33 holding.
American Financial Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2018 and has held it in 31 quarters since.
American Financial Advisors's State Street SPDR S&P Biotech ETF position peaked at $29.8M in Q3 2021.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on American Financial Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.